Befotertinib

small molecule

Identifier: CI-DRUG-00000102
Entity page: /drug/befotertinib ↗
Edges: 11

Neighbours: 2 cancers8 trials
Drawn: 10 of 10 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Befotertinib investigated for …INVESTIGATED_FOR1 of 1
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	2	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
Befotertinib investigated in trials for …INVESTIGATED_IN_TRIALSderived2 of 2

Befotertinib studied in …STUDIED_INderived8 of 8
→ studied in	NCT07410611Phase 2 · not yet recruiting ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · 8 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07181499Phase 2 · recruiting Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI · 8 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06863506Phase 2 · recruiting Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC · 8 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007938Phase 2 · unknown Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer · 8 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06561620Phase 4 · recruiting Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients · 8 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06517953Phase 2 · recruiting Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations · 8 trials list this drug (5 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03861156Phase 2 · completed D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer · 8 trials list this drug (5 active)	—	—	Solid Neoplasm,Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03452150Phase 1 · completed D-0316 First Time in Patients Ascending Dose Study · 8 trials list this drug (5 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Befotertinib studied in …STUDIED_INderived8 of 8

→ studied in

NCT07410611Phase 2 · not yet recruiting

ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · 8 trials list this drug (5 active)

—

Lung Non-Small Cell Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT07181499Phase 2 · recruiting

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI · 8 trials list this drug (5 active)

—

Lung Non-Small Cell Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT06863506Phase 2 · recruiting

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC · 8 trials list this drug (5 active)

—

Lung Non-Small Cell Carcinoma

Observed

clinicaltrials